Biotech - Spark Newswire

1 minute read

AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says

Today, 2:48 AM

Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…

ABBV

1 minute read

JNJ’s Consumer Health Business Separation Will Remove Uncertainty Cloud From Company: Why This Analyst Wants Visibility

By Vandana Singh

Today, 2:48 AM

Guggenheim initiated the coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a $161 price target. The analyst agrees with the…

JNJ

1 minute read

Analyst Sits On Fence While Initiating Calliditas Citing ‘Near-Term Opportunity But Longer-Term Questions’

By Vandana Singh

Today, 2:48 AM

Guggenheim initiated coverage on Calliditas Therapeutics AB (NASDAQ:CALT) with a Neutral rating and an $18 price target. The analyst is impressed with…

CALT

1 minute read

Guggenheim Creates Bullish Pitch For ANI Pharma On Progress With Cortrophin Launch

By Vandana Singh

Today, 2:48 AM

Guggenheim launched its coverage on ANI Pharmaceuticals Inc (NASDAQ:ANIP) with a price target of $55 and a Buy recommendation citing a “bullish view”…

ANIP

1 minute read

Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside

By Vandana Singh

Today, 2:48 AM

Guggenheim starts coverage on Chinook Therapeutics Inc (NASDAQ:KDNY) with a Buy rating and a $43 price target, being ‘bullish’ on the immunoglobulin…

KDNY

2 minute read

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer ‘Tranq’ Or ”Zombie Drug’

By Vandana Singh

Today, 2:48 AM

The FDA issued an “import alert” about the animal tranquilizer xylazine, also called “tranq,” “tranq dope,” and “zombie drug.” The…

BBH

2 minute read

Jim Cramer Says He’s Known Novavax Is ‘Worthless’ For ‘Very Long Time,’ Trashes Company For Being Too ‘Promotional’

By Adam Eckert

Today, 2:48 AM

Novavax Inc (NASDAQ: NVAX) shares are crashing Wednesday after the company warned that substantial doubt exists regarding its ability to continue. Jim Cramer isn't surprised.

EBS

1 minute read

After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung Cancer Patients

By Vandana Singh

Today, 2:48 AM

Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual primary endpoints, event-free survival…

MRK

1 minute read

Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection

By Vandana Singh

Today, 2:48 AM

Cidara Therapeutics Inc (NASDAQ: CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388 against the H3N2 influenza A virus strain.

CDTX

1 minute read

IVERIC bio’s Geographic Atrophy Candidate Shows Significant Reduction In Disease Progression

By Vandana Singh

Today, 2:48 AM

IVERIC bio Inc (NASDAQ:ISEE) announced an exploratory time-to-event analysis from the avacincaptad pegol (ACP) GATHER clinical trial program evaluating the reduction…

ISEE